1. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin. 2010;28:639-54.

2. Angeli F, Reboldi G, Poltronieri C et al. Efficacy and safety profile of aliskiren: practical implications for clinicians. Curr Drug Saf. 2014; 9:106-17.

3. Aronow WS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011;123:2434-2506.

4. Beckett N, Peters R, Leonetti G et al. HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014;32:1478-87.

5. Bulpitt CJ, Beckett N, Peters R et al. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension 2013; 61:89-94.

6. Cacciolati C, Tzourio C, Hanon O. Blood pressure variability in elderly persons with white-coat and masked hypertension compared to those with normotension and sustained hypertension. Am J Hypertens. 2013;26:367-372.

7. Chapman N, Chen CY, Fujita T et al.Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J. Hypertens. 2010;28:1796-1803.

8. Chen Y, Meng L, Shao H, Yu F. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. Hypertens Res. ,2013;36:252-61.

9. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 Report. JAMA 2003; 289:2560 - 2572.

10. Chrysant SG. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgrad Med. 2011;123:21-31.

11. Clark CE, Taylor RS, Shore AC et al.Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012;379 (9819): 905-914.

12. Cooper-DeHoff RM, Gong Y, Handberg EM et al.Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68.

13. Di Nicolantonio JJ. Hydrochlorothiazide: is it a wise choice? Expert Opin Pharmacother. 2012;13:807-14.

14. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat. Rev. Cardiol. 2011;8:13-28.

15. Foo L, Tay J, Lees CC et al. Hypertension in pregnancy: natural history and treatment options. Curr HypertensRep. 2015,17(5):36. doi: 10.1007/s11906-015-0545-1

16. Franklin SS, O’Brien E, Thijs L et al. Masked Hypertension. A Phenomenon of Measurement, Hypertension. 2015;65:16 -20.

17. Holzgreve H. Health and longevity by one tablet daily. Fiction and hard facts on the polypill (in German). MMW Fortschr Med. 2014;156:55-7.

18. James PA, Oparil S, Carter BL et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520.

19. Jiang N, Liu Q, Liu L et al.The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. Clin Exp Obstet Gynecol. 2015; 42:79-81.

20. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31: 2115-2127.

21. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34:2159 -2219.

22. Nguyen C, Cheng-Lai A. The polypill a potential global solution to cardiovascular disease. Cardiology in Review 2013; 21:49-5.

23. Ogihara T, Saruta T, Rakugi H et al. Target blood pressure for treatment of isolated systolic hypertension, in the elderly: Valsartan in Elderly Isolated Systolic Hypertension, Study. Hypertension 2010; 56:196-202.

24. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension, diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011; 24:52-58.

25. Prejbisz A, Januszewicz A. Antagoniści aldosteronu w terapii opornego nadciśnienia tętniczego. Terapia 2014; 22;43-50.

26. Sundrö m J i wsp. The Blood Pressure Lowering Treatment Trialists’ Collaboration Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384(9943):591-8.

27. Vaclavik J, Sedlak R, Plachy M. et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-1075.

28. White WB, Gulati V. Managing hypertension with ambulatory blood pressure monitoring. Curr Cardiol Rep. 2015 Feb;17(2):2. doi: 10.1007/s11886-014-0556-6.

29. Wiley B, Fuster V. The concept of the polypill in the prevention of cardiovascular disease. Ann Glob Health. 2014; 80:24-34.

30. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku Grupa Robocza Europejskiego Towarzystwa Nadciśnienia Tętniczego (ESH) i Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw postępowania w nadciśnieniu tętniczym. Kardiol Pol. 2013; 71, supl. III: 27–118 DOI: 10.5603/KP.2013.0177 ISSN 0022–9032.

31. Xu W, Goldberg SI, Shubina M et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj. h158 - Published 05 February 2015.

32. Yang L, Li L, Lewington S et al. China Kadoorie Biobank Study Collaboration. Outdoor temperature, blood pressure, and cardiovascular disease mortality among 23 000 individuals with diagnosed cardiovascular diseases from China. Eur Heart J. 2015; 36:1178-85.

33. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal. J Hypertens. 2009; 27: 923-9345.

34. Zhang Y, Zhang X, Liu L et al. Is a systolic blood pressure target, 140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011; 32:1500-1508.

(pełna lista zawierająca 58 pozycji – u Autorów)